Unum Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch UMRX and buy or sell other stocks, ETFs, and their options commission-free!About UMRX
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17.
CEOAndrew R. Robbins, MBA
CEOAndrew R. Robbins, MBA
Employees205
Employees205
HeadquartersWaltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded2014
Founded2014
Employees205
Employees205
UMRX Key Statistics
Market cap1.07B
Market cap1.07B
Price-Earnings ratio-6.11
Price-Earnings ratio-6.11
Dividend yield—
Dividend yield—
Average volume2.84M
Average volume2.84M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$17.15
52 Week high$17.15
52 Week low$3.72
52 Week low$3.72
Stock Snapshot
With a market cap of 1.07B, Unum Therapeutics(UMRX) trades at $9.40. The stock has a price-to-earnings ratio of -6.11.
On 2025-11-06, Unum Therapeutics(UMRX) stock opened at —, reached a high of —, and a low of —.
Unum Therapeutics(UMRX) shares are trading with a volume of 0, against a daily average of 2.84M.
During the past year, Unum Therapeutics(UMRX) stock moved between $3.72 at its lowest and $17.15 at its peak.
During the past year, Unum Therapeutics(UMRX) stock moved between $3.72 at its lowest and $17.15 at its peak.
People also own
Based on the portfolios of people who own UMRX. This list is generated using Robinhood data, and it’s not a recommendation.